FM6 148
e u r o p e a n u r o l o g y , vo l . 7 3 , n o . 1 , J a nu a ry 2 0 1 8
31
The “PROMIS” of Magnetic Resonance Imaging Cost Effectiveness in Prostate Cancer Diagnosis?J. Walz
33
Improved Recovery of Erectile Function in Younger Men after Radical Prostatectomy: Does it Justify Immediate Surgery in Low-risk Patients?J.K. Lee, D.D. Sjoberg, M.I. Miller, A.J. Vickers, J.P. Mulhall, B. Ehdaie
Active surveillance leads to better overall erectile function even where patients
are subject to delayed treatment.
38
Erectile Function Recovery After Surgery in Young Men with Low-risk Prostate Cancer: Probably Not Just a Matter of Age, Certainly Not the Main Point of DiscussionP. Capogrosso, F. Montorsi
40
Curative Treatment for Muscle Invasive Bladder Cancer in Elderly Patients: A Systematic ReviewV. Fonteyne, P. Ost, J. Bellmunt, J.P. Droz, P. Mongiat-Artus, B. Inman, E. Paillaud, F. Saad,
G. Ploussard
Elderly patients with muscle invasive bladder cancer treated with curative treatment
have acceptable outcomes, although it worsens with age. Late morbidity
is comparable between older and younger patients. Studies evaluating the impact
of using geriatric assessments are needed.
51
Bladder Cancer in the ElderlyM. Babjuk
53
Intravenous Mannitol Versus Placebo During Partial Nephrectomy in Patients with Normal Kidney Function: A Double-blind, Clinically-integrated, Randomized TrialM. Spaliviero, N.E. Power, K.S. Murray, D.D. Sjoberg, N.E. Benfante, M.L. Bernstein, J. Wren,
P. Russo, J.A. Coleman
Using intravenous mannitol intraoperatively to mitigate the effects of renal ischemia
during nephron-sparing surgery was not associated with improved renal function
outcomes in this prospective, randomized, placebo-controlled, double-blind trial;
the practice should be discontinued.
60
Should Urologists Abandon the Use of Mannitol During Partial Nephrectomy?P.H. Shah, B.C. Leibovich, T.D. Lyon
62
Adjuvant Sunitinib for High-risk Renal Cell Carcinoma After Nephrectomy: Subgroup Analyses and Updated Overall Survival ResultsR.J. Motzer, A. Ravaud, J.-J. Patard, H.S. Pandha, D.J. George, A. Patel, Y.-H. Chang, B. Escudier,
F. Donskov, A. Magheli, G. Carteni, B. Laguerre, P. Tomczak, J. Breza, P. Gerletti, M. Lechuga,
X. Lin, M. Casey, L. Serfass, A.J. Pantuck, M. Staehler
Further to the positive outcome in the overall S-TRAC population, most subgroups
defined by baseline characteristics demonstrated longer disease-free survival
on sunitinib versus placebo, including patients with a higher risk of recurrence than
the overall population, and patients with Fuhrman grade 3/4.
69
Are We Ready for Adjuvant Sunitinib in High-risk Renal Cell Carcinoma?J. Casuscelli, J.J. Hsieh
71
Characterization of Clinical Cases of Advanced Papillary Renal Cell Carcinoma via Comprehensive Genomic ProfilingS.K. Pal, S.M. Ali, E. Yakirevich, D.M. Geynisman, J.A. Karam, J.A. Elvin, G.M. Frampton, X. Huang,
D.I. Lin, M. Rosenzweig, D. Lipson, P.J. Stephens, J.S. Ross, V.A. Miller, N. Agarwal, B. Shuch,
T.K. Choueiri, J.H. Chung
Papillary renal cell carcinoma (PRCC) is a rare subtype of kidney cancer,
and understanding of the biology of advanced PRCC is limited. This report highlights
some of the unique biologic features of PRCC that may inform on future use
of targeted therapies for the treatment of metastatic disease.
Bladder Cancer
Kidney Cancer